Abbott signs licensing, supply deal with Zydus Cadila

12 May 2010 Evaluate

US-based drug maker Abbott has signed a licensing and supply agreement with Zydus Cadila for 24 products to be sold in 15 emerging markets. The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases. The partnership will leverage Abbott's powerful emerging markets infrastructure to commercialize the Zydus products, with product launches beginning in early 2012.

Under the agreement, Abbott will gain rights to at least 24 Zydus products in 15 key emerging markets where Abbott has a strong and growing presence. The agreement also includes an option for the addition of more than 40 Zydus products to the collaboration.

Pharmaceutical sales in emerging markets, including India, China and Brazil are expected to grow at three times the rate of developed markets. As per the industry estimates, the total market for pharmaceutical products is around $600 billion.crackcrack

Abbott India Share Price

27829.85 131.70 (0.48%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×